Landmark Analysis from Memorial Sloan Kettering Reveals Genomic Tumor Sequence of More Than 10,000 Cancer Patients Using MSK-IMPACT™
New York, NY, Monday, May 8, 2017 – Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful […]